Patents by Inventor David J. Mangelsdorf
David J. Mangelsdorf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220257716Abstract: The present invention relates to the treatment of secretory disorders, and provides novel methods of treatment of these disorders comprising the administration of fibroblast growth factor 21 (FGF21) or derivatives thereof. The methods of the invention are useful in conditions including exocrine pancreatic insufficiency (EPI), for example EPI resulting from cystic fibrosis, alcoholism, pancreatitis, pancreatic cancer, gallstones, celiac disease, high triglycerides, or lupus. The methods of the present invention find further utility in the treatment of salivary flow disorders, for example Sjorgen's syndrome, and the prevention of EPI or pancreatitis resulting from surgical procedures.Type: ApplicationFiled: March 11, 2022Publication date: August 18, 2022Inventors: David J. Mangelsdorf, Steven A. Kliewer, Katie C. Coate, Genaro Hermandez
-
Patent number: 11318186Abstract: The present invention relates to the treatment of secretory disorders, and provides novel methods of treatment of these disorders comprising the administration of fibroblast growth factor 21 (FGF21) or derivatives thereof. The methods of the invention are useful in conditions including exocrine pancreatic insufficiency (EPI), for example EPI resulting from cystic fibrosis, alcoholism, pancreatitis, pancreatic cancer, gallstones, celiac disease, high triglycerides, or lupus. The methods of the present invention find further utility in the treatment of salivary flow disorders, for example Sjorgen's syndrome, and the treatment of EPI or pancreatitis resulting from surgical procedures.Type: GrantFiled: May 24, 2017Date of Patent: May 3, 2022Assignee: Board of Regents, The University of Texas SystemInventors: David J. Mangelsdorf, Steven A. Kliewer, Katie C. Coate, Genaro Hernandez
-
Publication number: 20190201490Abstract: The present invention relates to the treatment of secretory disorders, and provides novel methods of treatment of these disorders comprising the administration of fibroblast growth factor 21 (FGF21) or derivatives thereof. The methods of the invention are useful in conditions including exocrine pancreatic insufficiency (EPI), for example EPI resulting from cystic fibrosis, alcoholism, pancreatitis, pancreatic cancer, gallstones, celiac disease, high triglycerides, or lupus. The methods of the present invention find further utility in the treatment of salivary flow disorders, for example Sjorgen's syndrome, and the prevention of EPI or pancreatitis resulting from surgical procedures.Type: ApplicationFiled: May 24, 2017Publication date: July 4, 2019Inventors: David J. Mangelsdorf, Steven A. KLIEWER, Katie C. COATE, Genaro HERNANDEZ
-
Patent number: 10117878Abstract: An effective anti-nematode methodology entails contacting nematodes with a biologically effective amount of at least one compound according to formula I: where Q, Q?, R1, R2, and n are defined herein, or with a stereoisomer, solvate, or pharmaceutically acceptable salt of such compound.Type: GrantFiled: November 9, 2012Date of Patent: November 6, 2018Assignee: Board of Regents, University of Texas SystemInventors: David J. Mangelsdorf, Richard J. Auchus, Daniel L. Motola, Carolyn L. Cummins, Kamalesh K. Sharma
-
Patent number: 8007994Abstract: The present invention relates to compositions and methods for reducing cholesterolemia and its effects. More specifically, the invention is directed, in one embodiment, to methods for screening for compounds that affect cholesterol levels generally, and in particular, that affect the absorption of cholesterol. The invention also is directed to methods of screening for compounds that increase bile acid synthesis. In so doing, the inventors describe useful transgenic cells and animals which lack one or both alleles of the LXR? gene. Also provided are therapeutic methods designed to reduce cholesterol levels in suitable subjects. The reduction may be effected by decreasing cholesterol absorption, increasing bile acid synthesis, or combinations thereof. Particularly useful in decreasing cholesterol absorption are RXR agonists, for example, rexinoid compounds. Therapeutic intervention in cholesterol biosynthesis and diet are additional adjunct therapies.Type: GrantFiled: December 22, 2004Date of Patent: August 30, 2011Assignee: The Board of Regents of the University of Texas SystemInventors: David J. Mangelsdorf, Joyce J. Repa, Stephen D. Turley, John M. Dietschy
-
Publication number: 20110028443Abstract: An effective anti-nematode methodology entails contacting nematodes with a biologically effective amount of at least one compound according to formula I: where Q, Q?, R1, R2, and n are defined herein, or with a stereoisomer, solvate, or pharmaceutically acceptable salt of such compound.Type: ApplicationFiled: October 15, 2010Publication date: February 3, 2011Inventors: David J. MANGELSDORF, Richard J. AUCHUS, Daniel L. MOTOLA, Carolyn L. CUMMINS, Kamalesh K. SHARMA
-
Patent number: 7825269Abstract: Anti-nematode compounds, compositions, and methods for identifying such compounds are disclosed, where the compounds have the formula I: where Q, Q?, R1, R2, and n are defined herein.Type: GrantFiled: March 8, 2007Date of Patent: November 2, 2010Assignee: Board of Regents, University of Texas SystemInventors: David J. Mangelsdorf, Richard J. Auchus, Daniel L. Motola, Carolyn L. Cummins, Kamalesh K. Sharma
-
Patent number: 7501487Abstract: The present invention relates to novel receptor polypeptides, which, upon interaction with certain ligands, or activation by certain compounds, modulate transcription of certain genes by binding to cognate response elements associated with promoters of such genes. The novel receptors of the invention modulate transcription in the presence of retinoid compounds. The receptors of the present invention differ significantly from known retinoic acid receptors, in protein primary sequence and in responsiveness to exposure to various retinoids. The invention provides DNAs encoding the novel receptors, expression vectors for expression of the receptors, cells transformed with such expression vectors, cells co-transformed with such expression vectors and with reporter vectors to monitor modulation of transcription by the receptors, and methods of using such co-transformed cells in screening for compounds which are capable, directly or indirectly, of activating the receptors.Type: GrantFiled: June 5, 1995Date of Patent: March 10, 2009Assignee: The Salk Institute for Biological StudiesInventors: David J. Mangelsdorf, Ronald M. Evans
-
Patent number: 7056954Abstract: In accordance with the present invention, there are provided methods to modulate processes mediated by retinoid receptors, employing high affinity, high specificity ligands for such receptors. In one aspect of the present invention, there are provided ligands which are more selective for the retinoid X receptor than is retinoic acid (i.e., rexoids). In another aspect of the present invention, alternative ligands (other than retinoic acid) have been discovered which are capable of inducing retinoic acid receptor mediated processes. In yet another aspect, methods have been developed for the preparation of such retinoid receptor ligands from readily available compounds.Type: GrantFiled: June 10, 2003Date of Patent: June 6, 2006Assignees: The Salk Institute for Biological Studies, Baylor College of Medicine, Ligand Pharmaceuticals, Inc.Inventors: Ronald M. Evans, David J. Mangelsdorf, Richard A. Heyman, Marcus F. Boehm, Gregor Eichele, Christina Thaller
-
Patent number: 6992108Abstract: A method for modulating lipid metabolism in a subject by administering 9-cis retinoic acid is presented. The 9-cis retinoic acid is more specific for the retinoid X receptor than is retinoic acid.Type: GrantFiled: June 7, 1995Date of Patent: January 31, 2006Assignees: The Salk Institute for Biological Studies, Baylor College of Medicine, Ligand Pharmaceuticals, Inc.Inventors: Ronald M. Evans, David J. Mangelsdorf, Richard A. Heyman, Marcus F. Boehm, Gregor Eichele, Christina Thaller
-
Patent number: 6835866Abstract: The present invention relates to compositions and methods for reducing cholesterolemia and its effects. More specifically, the invention is directed, in one embodiment, to methods for screening for compounds that affect cholesterol levels generally, and in particular, that affect the absorption of cholesterol. The invention also is directed to methods of screening for compounds that increase bile acid synthesis. In so doing, the inventors describe useful transgenic cells and animals which lack one or both alleles of the LXR&agr; gene. Also provided are therapeutic methods designed to reduce cholesterol levels in suitable subjects. The reduction may be effected by decreasing cholesterol absorption, increasing bile acid synthesis, or combinations thereof. Particularly useful in decreasing cholesterol absorption are RXR agonists, for example, rexinoid compounds. Therapeutic intervention in cholesterol biosynthesis and diet are additional adjunct therapies.Type: GrantFiled: December 10, 1999Date of Patent: December 28, 2004Assignee: Board of Regents, The University of Texas SystemsInventors: David J. Mangelsdorf, Joyce J. Repa, Stephen D. Turley, John M. Dietschy
-
Publication number: 20040006144Abstract: In accordance with the present invention, there are provided methods to modulate processes mediated by retinoid receptors, employing high affinity, high specificity ligands for such receptors. In one aspect of the present invention, there are provided ligands which are more selective for the retinoid X receptor than is retinoic acid (i.e., rexoids). In another aspect of the present invention, alternative ligands (other than retinoic acid) have been discovered which are capable of inducing retinoic acid receptor mediated processes. In yet another aspect, methods have been developed for the preparation of such retinoid receptor ligands from readily available compounds.Type: ApplicationFiled: June 10, 2003Publication date: January 8, 2004Applicant: The Salk Institute for Biological StudiesInventors: Ronald M. Evans, David J. Mangelsdorf, Richard A. Heyman, Marcus F. Boehm, Gregor Eichele, Christina Thaller
-
Patent number: 6576676Abstract: In accordance with the present invention, there are provided methods to modulate processes mediated by retinoid receptors, employing high affinity, high specificity ligands for such receptors. In one aspect of the present invention, there are provided ligands which are more selective for the retinoid X receptor than is retinoic acid (i.e., rexoids). In another aspect of the present invention, alternative ligands (other than retinoic acid) have been discovered which are capable of inducing retinoic acid receptor mediated processes. In yet another aspect, methods have been developed for the preparation of such retinoid receptor ligands from readily available compounds.Type: GrantFiled: July 9, 1999Date of Patent: June 10, 2003Assignees: The Salk Institute for Biological Studies, Baylor College of Medicine, Ligand Pharmaceuticals, Inc.Inventors: Ronald M. Evans, David J. Mangelsdorf, Richard A. Heyman, Marcus F. Boehm, Gregor Eichele, Christina Thaller
-
Publication number: 20030105166Abstract: In accordance with the present invention, there are provided methods to modulate processes mediated by retinoid receptors, employing high affinity, high specificity ligands for such receptors. In one aspect of the present invention, there are provided ligands which are more selective for the retinoid X receptor than is retinoic acid (i.e., rexoids). In another aspect of the present invention, alternative ligands (other than retinoic acid) have been discovered which are capable of inducing retinoic acid receptor mediated processes. In yet another aspect, methods have been developed for the preparation of such retinoid receptor ligands from readily available compounds.Type: ApplicationFiled: July 9, 1999Publication date: June 5, 2003Inventors: RONALD M. EVANS, DAVID J. MANGELSDORF, RICHARD A. HEYMAN, MARCUS F. BOEHM, GREGOR EICHELE, CHRISTINA THALLER
-
Patent number: 6506917Abstract: In accordance with the present invention, there are provided methods to modulate processes mediated by retinoid receptors, employing high affinity, high specificity ligands for such receptors. In one aspect of the present invention, there are provided ligands which are more selective for the retinoid X receptor than is retinoic acid (i.e., rexoids). In another aspect of the present invention, alternative ligands (other than retinoic acid) have been discovered which are capable of inducing retinoic acid receptor mediated processes. In yet another aspect, methods have been developed for the preparation of such retinoid receptor ligands from readily available compounds.Type: GrantFiled: June 7, 1995Date of Patent: January 14, 2003Assignee: The Salk Institute for Biological StudiesInventors: Ronald M. Evans, David J. Mangelsdorf, Richard A. Heyman, Marcus F. Boehm, Gregor Eichele, Christina Thaller
-
Patent number: 5990163Abstract: In accordance with the present invention, ligands have been discovered which selectively bind retinoid X receptors. Such ligands can be used for the selective modulation of retinoid X receptor mediated processes. In a further aspect of the present invention, there are provided pharmaceutical compositions comprising a pharmaceutically acceptable vehicle containing at least one of the above-described selective ligands. Such compositions are useful, for example, for the treatment of a variety of retinoid X receptor mediated disease states.Type: GrantFiled: January 13, 1995Date of Patent: November 23, 1999Assignee: The Salk Institute for Biological StudiesInventors: Ronald M. Evans, David J. Mangelsdorf, Richard A. Heyman, Marcus F. Boehm, Margaret A. Harmon
-
Patent number: 5968989Abstract: In accordance with the present invention, there are provided methods to modulate processes mediated by retinoid receptors, employing high affinity, high specificity ligands for such receptors. In one aspect of the present invention, there are provided ligands which are more selective for the retinoid X receptor than is retinoic acid (i.e., rexoids). In another aspect of the present invention, alternative ligands (other than retinoic acid) have been discovered which are capable of inducing retinoic acid receptor mediated processes. In yet another aspect, methods have been developed for the preparation of such retinoid receptor ligands from readily available compounds.Type: GrantFiled: June 7, 1995Date of Patent: October 19, 1999Assignees: The Salk Institute for Biological Studies, Baylor College of Medicine, Ligand Pharmaceuticals, Inc.Inventors: Ronald M. Evans, David J. Mangelsdorf, Richard A. Heyman, Marcus F. Boehm, Gregor Eichele, Christina Thaller
-
Patent number: 5932622Abstract: A method for modulating non-malignant skin related disorders in a subject has been demonstrated with 9-cis retinoic acid. Wrinkling, acne, keratinization, differentiation and proliferation disorders are treated by administration of 9-cis retinoic acid alone or in a pharmaceutically acceptable carrier to a subject in need thereof.Type: GrantFiled: June 7, 1995Date of Patent: August 3, 1999Assignees: The Salk Institute for Biological Studies, Baylor College of Medicine, Ligand Pharmaceuticals, Inc.Inventors: Ronald M. Evans, David J. Mangelsdorf, Richard A. Heyman, Marcus F. Boehm, Gregor Eichele, Christina Thaller
-
Patent number: 5747661Abstract: The characterization of LXR.alpha., an orphan member of the nuclear hormone receptor superfamily that can function as a tissue-specific mediator of 9-cis retinoic acid (9cRA) is described herein. When expressed in cells, LXR.alpha. activates transcription in response to 9cRA on a distinct response element, termed an LXRE. Significantly, neither RXR homodimers nor RXR/RAR heterodimers are able to substitute for LXR.alpha. in mediating this retinoid response. The LXR.alpha. response to retinoids is due to its unique interaction with endogenous RXR. This interaction shifts RXR from its previously described role as a silent, heterodimer partner to an active ligand binding partner, thus defining a novel retinoid response pathway.Type: GrantFiled: January 13, 1995Date of Patent: May 5, 1998Assignee: Howard Hughes Medical InstituteInventors: Ronald M. Evans, David J. Mangelsdorf, Patricia J. Willy
-
Patent number: 5723329Abstract: The present invention relates to novel receptor polypeptides, which, upon interaction with certain ligands, or activation by certain compounds, modulate transcription of certain genes by binding to cognate response elements associated with promoters of such genes. The novel receptors of the invention modulate transcription in the presence of retinoid compounds. The receptors of the present invention differ significantly from known retinoic acid receptors, in protein primary sequence and in responsiveness to exposure to various retinoids. The invention provides DNAs encoding the novel receptors, expression vectors for expression of the receptors, cells transformed with such expression vectors, cells co-transformed with such expression vectors and with reporter vectors to monitor modulation of transcription by the receptors, and methods of using such co-transformed cells in screening for compounds which are capable, directly or indirectly, of activating the receptors.Type: GrantFiled: November 8, 1994Date of Patent: March 3, 1998Assignee: The Salk Institute for Biological StudiesInventors: David J. Mangelsdorf, Ronald M. Evans